TRAVERE THERAPEUTICS, INC. Restructuring Costs
TRAVERE THERAPEUTICS, INC. (TVTX) reported Restructuring Costs of $100.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2024-10-31
- TRAVERE THERAPEUTICS, INC. restructuring costs for the quarter ending 2024-09-30 was $100.00K.
- TRAVERE THERAPEUTICS, INC. restructuring costs for the quarter ending 2024-06-30 was $700.00K.
- TRAVERE THERAPEUTICS, INC. restructuring costs for the quarter ending 2024-03-31 was $300.00K.
- TRAVERE THERAPEUTICS, INC. restructuring costs for the quarter ending 2017-09-30 was $1.13M.
- TRAVERE THERAPEUTICS, INC. restructuring costs for fiscal 2023 was $11.40M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 4 month | Restructuring Costs 6 month | Restructuring Costs 7 month | Restructuring Costs 9 month | Restructuring Costs 10 month | Restructuring Costs 12 month |
|---|---|---|---|---|---|---|---|
| 2024-09-30 | $100.00K 10-Q · filed 2024-10-31 | $800.00K derived: sum of 2 quarters · filed 2024-10-31 | $1.00M 10-Q · filed 2024-10-31 | $12.40M 10-Q · filed 2024-10-31 | |||
| 2024-06-30 | $700.00K 10-Q · filed 2024-08-01 | $900.00K 10-Q · filed 2024-08-01 | $12.30M 10-Q · filed 2024-08-01 | ||||
| 2024-03-31 | $300.00K 10-Q · filed 2024-05-06 | $11.70M 10-Q · filed 2024-05-06 | |||||
| 2023-12-31 | $11.40M 10-K · filed 2024-02-20 | ||||||
| 2017-09-30 | $1.13M 10-Q · filed 2017-11-07 | $2.61M 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |